MEDBRIGHT AI LATEST NEWS:
SYMBOL: OTCQB: MBAIF; CSE: MbAI
- Outstanding Shares: 110,369,555 (as of 10/09/2024)
- Float: 105,612,555 (as of 06/21/2024)
- medbright.ai
MedBright AI is a capital allocator focused on investing in healthcare technology companies.
MedBright’s mission is to construct a portfolio of synergistic investments that generate superior returns for shareholders. The company’s strategic investments combine to create a leading AI-platform, MedMatrix, with trained models powered by machine learning to continuously learn and create operational efficiencies in the healthcare space.
Solving the $200B Waiting Room Problem
- The problem: Sitting in a waiting room is a symptom of a massive pain point for patients and doctors – the broken resource matching system in healthcare.
- Patients are usually assigned a standard 20 minute time slot on a first come, first served basis rather than by actual medical and time needs.
- Patients waste time, doctors work longer hours and face burnout due to backups in the schedule, and clinics lose revenue.
Introducing MedBright’s Flagship Product
MedMatrix uses artificial intelligence to predict patient needs and dynamically prioritize resources to meet them, improving clinic revenue, patient satisfaction and physician burnout.
Helping Solve the Waiting Room Problem
How MedMatrix Works
Converting existing healthcare data into AI-powered improvements
First Mover in Massive Market
10% Improvement in $2.2T market is $220B opportunity
Targeting 1% penetration into outpatient market in next 24 months to potentially result in $300M/yr revenue with 80% margins.
Healthcare Services
$2.2 Trillion
Resource matching is a traditionally ignored problem
Technology solutions have focused on digital transformation of healthcare records and diagnostic capabilities, not on operational overhead. The complexity of scheduling could not be solved previously without new technology breakthroughs in AI and predictive analytics.
Outpatient Services
$660 Billion
Technology is ready for immediate commercialization
Platform is ready for use, built by proven team who previously developed AI-powered resource matching technology serving 30M customers per month.
MedBright Initial
Outpatient Focus
$6.6B
Go To Market Playbook
Prove value in outpatient clinics to grow into inpatient services
First target market: outpatient clinics
Goal to have $100M-$150M of clinic revenue using MedMatrix in coming months and increase those revenues in clinics by 10%.
Proven outpatient success opens access to hospitals and inpatient services
Expands addressable market from $660B to $2.2T in US alone, representing $220B of untapped revenue that MedMatrix can unlock.
Unique business model allows for rapid commercialization
MedMatrix requires no new administrator training, and noupfront cost to clinic.
Clinical Dashboard
Identify optimizations and improvements for clinics in real time
Predict patients’ needs
50+ different data sets are analyzed to predict patient needs and resource utilization in clinics. Includes EHR’s, claims data, credit data, and others, to accurately predict patient behavior in real-time.
Increased Revenue
In beta testing, MedMatrix saw a 12% increase in revenue due to dynamic scheduling and resource matching with no additional changes or costs.
Companies from MedBright’s portfolio across healthcare and technology
2022 Healthcare
First Person™ is building the leading brand dedicated to brain health and cognitive performance optimization. First Person’s world first precision-targeted supplement system works to isolate and amplify specific neurotransmitters (Dopamine, Oxytocin, and GABA) around key motor activities: energy, mood, and sleep.
2022 Artificial Intelligence
NetraMark was founded in 2016 by Dr. Joseph Geraci to address the current gaps in the pharmaceutical industry. NetraMark developed proprietary algorithms that can change the way AI is used in this industry. NetraMark developed proprietary algorithms that can change the way AI is used in this industry. NetraAI is a unique machine learning system that provides an intuitive interface for scientists to interact with multimodal datasets to uncover connections related to efficacy, toxicity and placebo response.
Mr. Dalsin is an investment expert with over 25 years experience specializing in healthcare products, technology and services. Mr. Dalsin was Chairman of Patient Home Monitoring, which has now become two Nasdaq companies: VieMed Healthcare Inc. (NASDAQ:VMD), and Quipt Home Medical (NASDAQ:QIPT). He was the founder and Industry Advisor to The Healthcare Special Opportunity Fund, a listed Canadian company. He has been asked to be a recurring guest lecturer at Yale University Medical School on the topic of fund flows and capital in the global healthcare economy.
Mr. Vieweg is a co-founder of Limmi, an AI platform focused on powering the world’s most complex healthcare data analytics systems. He previously served as the Chief Technology Officer of Sea Machines Robotics, a venture backed robotics start-up,as well as Head of Product Development at Viasat (NASDAQ:VSAT). He holds a bachelor’s degree in mechanical & aerospace engineering from Cornell University and a master’s degree in enterprise software architecture from the University of California San Diego.
Mr. Nathoo is an accomplished businessman having funded and managed various investments in the venture space over the past 30 years. Currently, Mr. Nathoo is Chairman & Chief Executive Officer for Vinergy Capital, Inc. Mr. Nathoo serves as Director of the Company. Mr. Nathoo is principal of a privately held hotel development company which over the past two decades has developed and sold over 10 hotels across Canada.
Mr. Vieweg is a co-founder of Limmi, an AI platform focused on powering the world’s most complex healthcare data analytics systems. He previously served as the Chief Technology Officer of Sea Machines Robotics, a venture backed robotics start-up, as well as Head of Product Development at Viasat (NASDAQ:VSAT). He holds a bachelor’s degree in mechanical & aerospace engineering from Cornell University and a master’s degree in enterprise software architecture from the University of California San Diego.
Dr. Gerber is a cardiologist specializing in preventive cardiology, as well as complex cardiology cases that involve coronary artery disease, peripheral artery disease, and risk factor modification. Additionally, Dr. Gerber is a Professor of Medicine at Yale Medical School, is the co-director of the Yale Executive Health program, and directs theYale New Haven Heart & Vascular Center laboratory for vascular ultrasound testing for peripheral arterial disease. He has broad experience in medical systems management and healthcare start-ups.
Dr. Wilks applies mission-driven, strategic thinking to improve hospital operations and patient outcomes as the CEO of Olive View-UCLA Medical Center in Los Angeles, CA, a 355-bed general acute care hospital that employs nearly 5,500 persons and has a $900-million dollar annual operating budget. She has over 25 years of experience as a dynamic, visionary leader in healthcare and the military. Prior to her role as CEO, she served as the Medical Director of Quality and Patient Safety Officer and Chief of Dental Services for Los Angeles County Health Services. Dr. Wilks is a U.S. Naval Academy graduate, naval officer, and combat veteran who fought in support of Operation Iraqi Freedom and Enduring Freedom in the Persian Gulf. She received her doctorate from the UCLA School of Dentistry.
Mr. Balderson has an extensive background in business and has worked in the capital markets for over 20 years. He currently acts as an officer and director of multiple TSX Venture and Canadian Securities Exchange listed companies. Mr. Balderson is the President of Harmony Corporate Services Ltd., a Vancouver based company that provides administrative services to publicly listed companies. Prior to this he was an Investment Advisor with two Canadian investment dealers. Mr. Balderson is a graduate of the Sauder School of Business at the University of British Columbia.
Mr. Cherry is a Chartered Accountant and Certified General Accountant with more than 15 years of corporate accounting and audit experience. In his former experience as an auditor, he held positions with KPMG and Davidson and C. LLP in Vancouver. He serves as a Director, CFO and Secretary on several public companies. Mr. Cherry is a CPA having obtained the Chartered Accountant designation in February 2009 and the Certified General Accountant designation in 2004. In his former experience as an auditor, he held positions with KPMG and Davidson and Co. LLP in Vancouver, where he gained experience as an auditor for junior public companies.
Recent News
- MedBright AI Announces the Appointment of Christopher Heath as CEO and Termination of Letter of Intent – August 9, 2024
- MedBright AI Issues Clarifying News Release on Continuous Disclosure Record – August 8, 2024
- MedBright AI Announces Strategic Acquisition by Numinus Wellness – June 20, 2024
- MedBright AI Announces New Commercial Product Demos for MedMatrix AI Platform – Mayy 2, 2024
- Southern California Clinic Signs Multi-Year Deal for MedMatrix AI Platform – April 16, 2024
- Rejuvenation Medical Group of Canada Uses MedMatrix AI Reporter to Streamline Reporting and Improve Operations – March 19, 2024
- Southern California Clinic uses MedMatrix AI Market Expander to Launch Opening of New Clinic Locations – March 12, 2024
- MedMatrix Go-to-Market Pricing Announced for AI Product Suite Addressing US$726 Billion Market – March 5, 2024
- MedMatrix Product Moves from Beta to Full Commercialization, Announces AI Product Suite – February 27, 2024
- MedBright AI Announces Limmi Disease Insights Platform Being Used in University Hospital Setting to Improve Detection of Kidney Stone Disease Recurrence – February 22, 2024
- MedBright AI’s MedMatrix to Expand Its AI Offerings for Cosmetic Marketing & Clinical Trial Analytics – January 23, 2024
- MedBright AI to Present at CEM Bahamas Small-Cap Conference and Maxim Group’s 2024 Healthcare IT Conference – January 19, 2024
- MedBright AI Reaches US$100M in Total Clinic Revenue Under Contract with MedMatrix, the AI-Powered Data Analytics Platform – January 18, 2024
- MedBright AI Announces Rejuvenation Medical Group, a Large Canadian Clinic Group, as First International Customer for MedMatrix, the AI-Driven Data and Analytics Platform – January 9, 2024
- MedBright AI Appoints Trevor Vieweg as Chief Executive Officer – January 4, 2024
- MedBright AI Announces Closing of Investment in Limmi Healthcare AI Platform – December 28, 2023
- MedBright AI Announces CareMEDICA, a Yale University School of Medicine Affiliated Clinic Group, as Beta Customer for MedMatrix, the AI-Driven Data and Analytics Platform – December 14, 2023
- MedBright AI Announces Beta Customer for MedMatrix, the AI-Driven Data and Analytics Platform – December 7, 2023
- MedBright AI Announces Election of Two US Healthcare Experts to Board of Directors and Approval of New Share Class – December 5, 2023
- MedBright AI Unveils New Investment Presentation Announcing MedMatrix, the AI-Driven Data Analytics and Improvement Platform – November 29, 2023
- MedBright AI Investments and The Ken Sperling Lecture Series Support Medical Economics Lectures at Yale University Medical School – November 22, 2023
- Vinergy Capital Inc. Announces Name Change to MedBright AI Investments Inc. – November 6, 2023
- Vinergy Capital Adds AI Expert to Investment Committee – October 19, 2023
- Vinergy Capital Finalizes Investment in Privately-Backed Healthcare AI Platform Company Adding to its Healthcare AI Portfolio – October 17, 2023
- Vinergy Capital Announces Closing of Non-Brokered Private Placement – October 3, 2023
- Vinergy Provides Update on Healthcare AI Investments and Highlights from New Investor Presentation – September 27, 2023
- Vinergy to Make Investment in Healthcare AI Platform Company to Compliment Recent Investment in Healthcare Trained Model Company; Michael Dalsin to Head Investment Committee – September 8, 2023
- Vinergy Completes Investment in Healthcare Accretion Group – August 30, 2023
Emerging markets Report
Must Read OTC Markets/SEC policy on stock promotion and investor protection
Disclaimer
EMC has been paid $90,000 by MedBright AI Investments Inc. | Please read our full disclaimer
By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact